Agilent Technologies, Inc. (A)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$173.89
▼ -3.86 (2.17%)
Fair valueFair
$145 −16.9% to fair value
$72fair band $123–$175$217
Day's range
$171.23 – $179.00
52-week range
$108.35 – $179.00
About Agilent Technologies, Inc.
Agilent Technologies provides instruments, software, consumables and services for laboratories. Its products include liquid and gas chromatography systems, mass spectrometers, genomic and cell analysis tools, and diagnostic tests and reagents. Customers work in pharmaceuticals, diagnostics, chemicals, food testing, environmental testing and academic research. The company is organised into life sciences and applied markets, diagnostics and genomics, and a laboratory services business.
Agilent earns revenue from new instruments and from the recurring consumables, service contracts and software that laboratories use with them. Over the last twelve months it was $7.4 billion, growing at 0.5% a year across the last three years. The operating margin is 22.2%, and the business earns a profit of 15% on the capital invested in it. It carries net debt of 1.3 times EBITDA. A dividend is paid, with a yield of 0.6%. On the site's X-Ray Score it receives 40 out of 100.
Price chart
52-wk range $108.35 – $179.00Volume 2,654,506Daily, split-adjusted
Vitals
Market cap$49.2B
52-week range$108.35 – $179.00
Volume (last day)2,654,506
P/E (TTM)34.3
EBIT / EV yield3.2%
Free-cash-flow yield2.6%
Dividend yield0.6%
Revenue (TTM)$7.4B
Net income (TTM)$1.4B
Operating margin22.2%
Return on capital14.6%
Debt incl. leases$4.1B
Cash & securities$1.8B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies that hold large long-term investments). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$145middle half of models $110 – $172
Fair
−16.9% to fair value
Average of the 14 valuation models that pass our checks: multiples, discounted cash flow, dividend discount and earnings power value. A model more than 100% above or 60% below the price is left out as unrealistic. Model uncertainty is Medium, based on how far apart the models are. Undervalued or Overvalued means the gap to fair value is more than 17.5%.
Price $174
Undervalued < $123Fair $123 – $175Overvalued > $175
P/E multiple
$171
P/B multiple
$172
P/S multiple
$172
EV/EBITDA multiple
$196
EV/EBIT multiple
$177
EV/revenue multiple
$173
10-year DCF, EBITDA exit
$155
5-year DCF, EBITDA exit
$167
10-year DCF, revenue exit
$153
5-year DCF, revenue exit
$166
10-year DCF, growth exit
$78
5-year DCF, growth exit
$75
Dividend discount, stable · not used
$42
Dividend discount, multi-stage
$73
Earnings power value
$95
Growth the price implies
20.4%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.13%, equity risk premium 4.30% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Strong: 70 to 100Fair: 50 to 69Weak: under 50No score: not enough data
Valuation
Weak
20/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.2%
Free-cash-flow yield2.6%
Fair value vs price0.8×
Growth
Weak
35/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)0.5%
EPS growth (3y)3.0%
Growth consistency80%
Profitability
Fair
52/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital14.6%
Operating margin22.2%
Gross profitability28.4%
Financial health
Fair
50/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA1.3×
Interest cover15.5×
Dividends
Fair
50/100
Dividend is typical for its sector.
See the numbers →
Dividend yield0.6%
Dividends vs free cash flow23%
Dividend growth4.1%
Quarterly results: last 6 quarters
+6.0%
Apr '25
+10.1%
Jul '25
+9.4%
Oct '25
+7.0%
Jan '26
+10.0%
Apr '26
+8.1%
Jul '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.9B, diluted EPS $1.28.
Compare with peers
MTD Mettler Toledo Interna...47 TECH BIO-TECHNE Corp45 IQV Iqvia Holdings Inc.43 ILMN Illumina, Inc.39Other Life Sciences Tools & Services companies by X-Ray Score.
SWOT analysis: Agilent Technologies, Inc.
Strengthsinside the company
- Return on invested capital is 14.6%, against a median of 8.5% for industry peers.
- Operating profit covers interest 15x, so debt costs are a small drag.
Weaknessesinside the company
- No clear weakness in the figures we track.
Opportunitiesvaluation and setting
- Revenue growth picked up to 6.7% last year from 0.5% a year over three years.
- Price momentum is strong on the weekly and monthly signals (trends can reverse).
Threatsvaluation and setting
- No specific threat is flagged by our checks; general market and interest-rate risk still applies.
Written by fixed rules from the figures on this page and the peer table below: filings, our fair value, the sector climate and the price trend. It summarises the data, it is not a forecast or advice.
Compare A with peers and sector
Medians of 8 Life Sciences Tools & Services peers and of 59 Health Care stocks in our universe.
Largest peers (X-Ray Score): TMO 34, DHR 30, IQV 43, WAT 33, ILMN 39, MTD 47.
| Metric | A | Peers | Sector |
|---|---|---|---|
| X-Ray Score (out of 100) | 40 | 37 | 49 |
| Valuation | 20 | 28 | 55 |
| Growth | 35 | 28 | 48 |
| Profitability | 52 | 41 | 49 |
| Financial health | 50 | 38 | 48 |
| Dividends | 50 | 40 | 52 |
Sector leaders: highest X-Ray Score in Health Care
A ranks #48 of 60 in Health Care and #4 of 9 in Life Sciences Tools & Services by X-Ray Score. A higher score is stronger on our five pillars; it is a ranking of facts, not a forecast.
Green means better than the peer median, red worse (only where a higher or lower figure is clearly better). A dash means too few companies report the figure. P/E, EV/EBITDA and price changes are not graded: a different level is not good or bad by itself.
Factor ratings for A
Each factor is rated by where A stands among the 60 Health Care stocks in our universe.
Rating against the sector
Goodthe top third of these stocks
Averagethe middle third of these stocks
Badthe bottom third of these stocks
"Beats" is the share of those stocks it is ahead of.
Against its own history
The last columns set today's figure against the company's own median of its last five financial years:
▲ Betterbetter than its usual level
▼ Worseworse than its usual level
≈ In linewithin its usual range
For valuation factors Good means cheaper than most of the sector and Better means cheaper than usual for this company, which is not the same as a bargain.
In total: 5 Good · 9 Average · 9 Bad of 23
Growth: 0 · 2 · 1
Profitability: 3 · 1 · 1
Financial strength: 2 · 1 · 1
Valuation: 0 · 2 · 3
Cash flow: 0 · 2 · 2
Efficiency: 0 · 1 · 1
| Factor | A | Rating | Sector median | Own 5-year median | Against own history |
|---|---|---|---|---|---|
| Growth | |||||
| Revenue growth, 3 years a year | +0.5% | Bad beats 16% | +5.5% | – | – |
| Revenue growth, last year | +6.7% | Average beats 46% | +7.1% | +6.7% | ≈ In line |
| EPS growth, 3 years a year | +3.0% | Average beats 44% | +5.0% | – | – |
| Profitability | |||||
| Gross margin | 53.8% | Bad beats 33% | 65.0% | 53.9% | ≈ In line |
| Operating margin | 22.2% | Good beats 71% | 16.4% | 21.3% | ≈ In line |
| Net margin | 19.5% | Good beats 77% | 11.1% | 18.8% | ≈ In line |
| Return on invested capital | 14.6% | Average beats 59% | 12.2% | – | – |
| Return on equity | 19.6% | Good beats 67% | 13.7% | 21.9% | ▼ Worse |
| Financial strength | |||||
| Net debt / EBITDA | 1.3x | Good beats 70% | 2.0x | 0.9x | ▼ Worse |
| Interest cover | 15.5x | Average beats 58% | 9.4x | 15.5x | ≈ In line |
| Current ratio | 2.05 | Good beats 74% | 1.52 | 2.09 | ≈ In line |
| Piotroski F-score | 5 / 9 | Bad beats 25% | 6 / 9 | – | – |
| Valuation | |||||
| P/E ratio | 34.2x | Average beats 37% | 28.2x | 32.0x | ≈ In line |
| Price / book | 6.7x | Average beats 34% | 3.7x | 6.4x | ≈ In line |
| Price / sales | 6.7x | Bad beats 23% | 3.7x | 6.0x | ▼ Worse |
| EV / EBITDA | 27.0x | Bad beats 27% | 17.6x | 22.9x | ▼ Worse |
| Free cash flow yield | 2.6% | Bad beats 18% | 4.4% | 2.8% | ≈ In line |
| Cash flow | |||||
| Free cash flow margin | 17.2% | Average beats 52% | 16.3% | 20.5% | ▼ Worse |
| Cash from operations / net income | 1.12 | Bad beats 15% | 1.61 | 1.23 | ≈ In line |
| Free cash flow growth, 3 years a year | +4.1% | Average beats 46% | +4.3% | – | – |
| Accruals (lower is better) | −1.2% | Bad beats 10% | −3.9% | – | – |
| Efficiency | |||||
| Inventory turnover | 3.0x | Average beats 52% | 2.9x | 3.2x | ≈ In line |
| Days sales outstanding | 73 days | Bad beats 25% | 62 days | 74 days | ≈ In line |
These ratings compare companies with each other and describe the past; they are not a forecast, a recommendation or part of the X-Ray Score. A factor is left out when its data is missing or meaningless (for example a P/E on negative earnings). A dash in the history columns means fewer than three usable years.
Fundamentals checklist
● 3 Good · ● 7 Average · ● 6 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldBad
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceBad
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginGood
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 40/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $6.3B | $6.8B | $6.8B | $6.5B | $6.9B |
| Operating income | $1.3B | $1.6B | $1.4B | $1.5B | $1.5B |
| Net income | $1.2B | $1.3B | $1.2B | $1.3B | $1.3B |
| Operating cash flow | $1.5B | $1.3B | $1.8B | $1.8B | $1.6B |
| Operating margin | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% |
| Free cash flow | $1.3B | $1.0B | $1.5B | $1.4B | $1.2B |
| Diluted EPS | $3.94 | $4.18 | $4.19 | $4.43 | $4.57 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 4 neutral · 0 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 173.1 | Bullish |
| EMA 10 | 173.0 | Bullish |
| SMA 20 | 171.8 | Bullish |
| EMA 20 | 170.2 | Bullish |
| SMA 50 | 160.8 | Bullish |
| EMA 50 | 161.5 | Bullish |
| SMA 100 | 147.8 | Bullish |
| EMA 100 | 151.2 | Bullish |
| SMA 200 | 134.7 | Bullish |
| EMA 200 | 141.8 | Bullish |
Oscillators (daily)
| RSI (14) | 58.86 | Neutral |
| MACD (12, 26) | 4.08 | Bullish |
| Momentum (12) | 2.69 | Bullish |
| Stochastic %K (14) | 67.41 | Neutral |
| Williams %R (14) | -32.59 | Neutral |
| CCI (20) | 89.75 | Neutral |
Pivot points (classic, last session)
S3 162.6 | S2 166.9 | S1 170.4 | Pivot 174.7 | R1 178.2 | R2 182.5 | R3 186.0 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
1.02 USD
Yield on today's price
0.59%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 0.2550 | |
| 0.2550 | |
| 0.2550 | |
| 0.2550 | |
| 0.2480 | |
| 0.2480 | |
| 0.2480 | |
| 0.2480 | |
| 0.2360 | |
| 0.2360 | |
| 0.2360 | |
| 0.2360 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ETFs that hold A
| ETF | Share of the fund |
|---|---|
| PHO Invesco Water Resources | 3.87% |
| FTCS First Trust Capital Strength | 2.20% |
| MOAT VanEck Morningstar Wide Moat | 1.38% |
| BKDV BNY Mellon Dynamic Value | 1.05% |
| VOT Vanguard Mid-Cap Growth | 0.82% |
| XLV Health Care Select Sector SPDR | 0.65% |
| IYH iShares U.S. Healthcare | 0.64% |
| VHT Vanguard Health Care | 0.61% |
The eight funds with the largest weight in A among the ETFs we cover, from each fund's latest SEC Form N-PORT (quarter-end positions, so they can be months old). All ETFs.
A SEC filings
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations
8-KSEC EDGAR
Entered a material agreement
10-QSEC EDGAR
Quarterly report
8-KSEC EDGAR
Results of operations; Director or officer change
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
8-KSEC EDGAR
Current report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.